S-1/A: Virpax Pharmaceuticals Announces Public Offering of Common Stock and Pre-Funded Warrants

Virpax Pharmaceuticals is offering up to 16,849,200 shares of common stock and pre-funded warrants to raise capital for clinical trials, working capital, and general corporate purposes.

Summary

• Virpax Pharmaceuticals is conducting a best efforts public offering of up to 16,849,200 shares of its common stock and pre-funded warrants.
• The offering aims to raise funds for commencing a clinical trial for Probudur, working capital, and general corporate purposes.
• The pre-funded warrants are offered to purchasers who would otherwise exceed a 4.99% (or 9.99%) ownership threshold, with each warrant exercisable for one share at $0.00001.
• The assumed public offering price is $0.3561 per share, based on the last reported sale price on January 13, 2025, but the actual price will be negotiated.
• Spartan Capital Securities, LLC is acting as the exclusive placement agent.
• The offering is expected to close on January 31, 2025, but may be terminated earlier.
• The company is an emerging growth company and a smaller reporting company, allowing for reduced reporting requirements.
• Net proceeds are estimated at $5.5 million, assuming all shares are sold at the assumed price and no pre-funded warrants are issued.
• The company will use $2.0 million for marketing and advertising services to communicate information about the Company to the financial community.

Sentiment

Score: 6

Explanation: The document is primarily factual, outlining the terms of the offering. While the capital raise is a positive step, the risks associated with the company's financial position and the offering itself temper the overall sentiment.

Positives

• The offering provides capital to fund the development of Probudur and other corporate activities.
• The company has engaged an experienced placement agent, Spartan Capital Securities, LLC.
• The company's status as an emerging growth company and smaller reporting company allows for reduced reporting requirements.
• The company will use $2.0 million for marketing and advertising services to communicate information about the Company to the financial community.

Negatives

• The offering is on a best efforts basis, meaning there is no guarantee that all shares will be sold.
• The company may receive significantly less than the estimated $5.5 million in net proceeds.
• The offering price is subject to negotiation and may be at a discount to the current market price.
• There is no established public trading market for the pre-funded warrants.
• The company's cash position is not sufficient to enable it to fund its operations through the first quarter of 2025.

Risks

• The company requires substantial additional capital to fund its operations, and if it fails to obtain necessary financing, it will not be able to complete the development and commercialization of its drugs.
• The company may face challenges in retaining key personnel and maintaining business continuity as a result of recent cost-cutting measures, including salary reductions, which may also affect its product development and timelines.
• The elimination of the company's directors and officers insurance may affect retention, expose its directors and officers to personal liability, and impact its financial condition.
• The cancellation of the company's cybersecurity insurance may expose it to increased financial and operational risks.
• The company may not be able to maintain a listing of its common stock on Nasdaq.
• If shares of the company's common stock become subject to the penny stock rules, it would become more difficult to trade its shares.
• If you purchase shares of the company's Common Stock sold in this offering, you will experience immediate and substantial dilution in the net tangible book value of your shares.
• There is no public market for the Pre-Funded Warrants being offered in this offering.

Future Outlook

The company intends to use the net proceeds from this offering to fund its ongoing development activities for commencing clinical trial for Probudur, as well as for working capital and other general corporate purposes. In addition, the company will use $2.0 million for marketing and advertising services to communicate information about the Company to the financial community.

Industry Context

This announcement reflects a common strategy for preclinical-stage pharmaceutical companies to raise capital through public offerings to fund research and development activities.

Comparison to Industry Standards

• Comparable companies in the pharmaceutical industry often utilize public offerings to finance clinical trials and drug development programs.
• The terms of the offering, including the use of pre-funded warrants, are structured to accommodate potential ownership limitations and regulatory requirements.
• The engagement of a placement agent is a standard practice for managing and distributing securities in such offerings.

Management Changes

Corporate Governance

Legal Proceedings

• The company entered into a Settlement Agreement and Mutual Release with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc. to resolve all claims related to litigation in the Chancery Court of the State of Delaware.
• The company agreed to pay Sorrento and Scilex a total cash payment of $6 million and royalties of 6% of annual net sales of products developed from drug candidates Epoladerm, Probudur and Envelta.
• The company received a letter from legal counsel to Gerald Bruce and Vinay Shah regarding their employment agreements, alleging violations due to compensation reductions, which the company disputes.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• Employees may be affected by cost-cutting measures and potential retention issues.
• The offering aims to secure funding for the development of new treatments, potentially benefiting patients.
• The company's ability to meet its financial obligations to suppliers and creditors depends on the success of the offering.

Next Steps

• The company will negotiate the final offering price with investors.
• The company will seek to close the offering by January 31, 2025.
• The company will apply to list the shares and warrant shares on the Nasdaq Capital Market.
• The company will commence a clinical trial for Probudur.

Key Dates

Keywords

public offering, common stock, pre-funded warrants, capital raise, Virpax Pharmaceuticals, Spartan Capital Securities, clinical trial, Probudur, securities, offering